Trials / Completed
CompletedNCT02192723
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 550 (actual)
- Sponsor
- Beijing HuiLongGuan Hospital · Academic / Other
- Sex
- All
- Age
- 25 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and side effects of 6 commonly used antipsychotic drugs in the treatment of schizophrenia in a Chinese population.
Detailed description
The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. The investigators compared a first-generation antipsychotic, perphenazine or haloperidol, with several newer drugs in a double-blind study. METHODS: A total of 550 patients with schizophrenia were recruited at 4 Chinese sites and randomly assigned to receive perphenazine (16 to 64 mg per day) or haloperidol(6 t0 20mg per day), olanzapine (5 to 20 mg per day), quetiapine (400 to 750 mg per day), aripiprazole (10 to 30 mg per day) or risperidone (2 to 6.0 mg per day) for up to 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Typical antipsychotic | Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks |
| DRUG | Risperidone | 2\~6mg/day, twice per day, 8 weeks |
| DRUG | Olanzapine | Olanzapine, 400\~750mg/day, twice per day, 8 weeks |
| DRUG | Quetiapine | Quetiapine, 400~750mg/day, twice per day, 8 weeks |
| DEVICE | Aripiprazole | Aripiprazole, 10~30mg/day, twice per day, 8 weeks |
| DRUG | Ziprasidone | Ziprasidone 80\~160mg/day, twice per day, 8 weeks |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2014-07-17
- Last updated
- 2016-07-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02192723. Inclusion in this directory is not an endorsement.